# Cognitive Neurology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Emile Griffith (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX005-SYN
- Date: 2026-05-19
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rafael Haddad-Lindgren, MD
- Calendar frame: modern shifted

- Requested by: Celeste Fairbanks-Ochieng, MD

## Reason for consultation

About a year of memory loss and confusion in a retired professional boxer of 67 with a long career, a severe assault with a head injury thirteen years ago, and chronic PTSD; MoCA 22. Please stage the impairment, weigh traumatic brain injury and traumatic encephalopathy syndrome against Alzheimer's disease, vascular disease and the effects of PTSD and depression, and advise on further testing, treatment and safety. **S**

## History

Mr. Griffith, 67, was seen with his care partner, who gave a consistent account with his permission. He boxed professionally for nineteen years, in 112 bouts, and cannot count the knockdowns or the times he was dazed. Thirteen years ago he was badly beaten and spent months in hospital; he and his care partner date the first memory lapses to that time, with a slow worsening over the past year rather than a sudden change. He now loses the thread of conversations, needs reminders, and finds names slow to come, though the names come with a hint. He has no headaches, seizures, tremor, change in walking beyond some unsteadiness, change in smell, dream enactment, hallucinations, impulsive behavior, rages or paranoia. He has nightmares about the title fight most nights and guilt about it, and sleeps about five hours. He started sertraline 25 mg two weeks ago, with nausea for three days that has passed. **S**

## Examination

| System | Finding |
|---|---|
| General | Well and warm; blood pressure 130/78 mmHg; pulse 68 |
| Cognition | Oriented except for the date; slow to retrieve the plan from intake but recalls it with cues; Clinical Dementia Rating global 0.5 (sum of boxes 2.0) from interviews with him and his care partner |
| Cranial nerves | Normal, including smell, eye movements and facial strength |
| Motor | Normal tone and strength; no tremor, rigidity or slowness of movement |
| Reflexes and coordination | Reflexes symmetric; plantar responses flexor; finger-nose and heel-shin normal |
| Gait | Slightly wide-based; one side-step on tandem walking; Romberg negative |
| Mood and behavior | Tearful briefly about the fight; no disinhibition, apathy or paranoia; denies thoughts of suicide |

BP 130/78 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 73.8 kg; BMI 25.5 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Fairbanks-Ochieng's intake note: MoCA 22, PHQ-9 9, PC-PTSD-5 4, PCL-5 41, Functional Activities Questionnaire 6, Timed Up and Go 13 seconds, normal blood count, metabolic panel, B12 and TSH; sodium 138 mmol/L today, two weeks into sertraline. Brain MRI this morning, reviewed with the images: mild generalized atrophy, more in the frontal lobes; hippocampi in the normal range for age (medial temporal atrophy score 1 on each side); a small old injury (encephalomalacia with hemosiderin) at the tip of the right frontal lobe; seven microbleeds at the gray-white junction of both frontal lobes; Fazekas 1 white matter change; a cavum septi pellucidi; no infarct, mass, subdural collection or hydrocephalus. Sodium: 138 mmol/L; CDR (global): 0.5. All results are synthetic.

## Assessment

1. **Mild cognitive impairment (CDR 0.5) of frontal-subcortical pattern** (R41.3). Slowed processing, poor set-shifting and retrieval that improves with cues, with preserved independence in daily life, fit mild cognitive impairment (mild neurocognitive disorder), not dementia. **S**
2. **Traumatic brain injury and traumatic encephalopathy syndrome** (Z87.820). Repetitive head impacts over a long career and the severe assault are the most likely causes; the MRI shows an old right frontal injury, frontal microbleeds and a cavum septi pellucidi, and spares the hippocampi. He probably meets the NINDS 2021 criteria for traumatic encephalopathy syndrome (substantial exposure, a core cognitive impairment, a progressive course, not fully accounted for by another condition). These are research criteria: they cannot confirm chronic traumatic encephalopathy in life, they are not a clinical diagnosis, and they do not change treatment. The single severe injury makes it impossible to separate the two exposures. **S**
3. **Alzheimer's disease and vascular disease**. Alzheimer's disease is less likely given the retrieval pattern and normal hippocampi, but co-pathology at 67 cannot be excluded. Vascular change is slight (Fazekas 1, no infarct). **S**
4. **Chronic PTSD, depressive symptoms and short sleep** (F43.12). These can impair attention and retrieval and are treatable; treating them is the best chance of improving his day-to-day thinking. Sertraline is a reasonable choice: it has no anticholinergic burden; sodium and falls need watching. Benzodiazepines, sedating sleep aids and anticholinergic drugs should be avoided. **S**

## Recommendations

1. Neuropsychological testing in about three weeks to define the pattern, confirm the stage and give a baseline for follow-up.
2. Alzheimer's disease biomarker testing (blood, CSF or amyloid PET) can be offered after the testing; it is optional if the result would not change his care, and with seven microbleeds he would not be a candidate for anti-amyloid antibodies whatever the result.
3. No cholinesterase inhibitor or memantine: neither is shown to help mild cognitive impairment or traumatic brain injury.
4. Continue sertraline and raise to 50 mg at six weeks if tolerated, with a sodium check two to four weeks after the change; continue cognitive processing therapy, adapted with written summaries, reminders and his care partner's help between sessions.
5. Memory strategies: one calendar, phone reminders and a fixed routine; daily exercise, social activity and regular sleep.
6. Safety: an address card, shared phone location and company on unfamiliar routes; shared oversight of bills; physical therapy for balance as already ordered.
7. Support for his care partner: education, the Alzheimer's Association helpline and a caregiver class; the GUIDE model applies only if dementia develops.
8. Advance care planning soon, while he can take part fully.
9. Repeat cognitive testing yearly and neuropsychological testing in twelve to eighteen months, or sooner with change; return to the memory clinic for faster decline, parkinsonism, behavioral change or a fall with head injury.

## Strengths and supports

- Strengths and supports: warmth, humor and generosity, pride in his career and in the fighters he trained, his care partner, family on the islands and in New York, and friends from boxing **S**

## Communication

Discussed with Dr. Fairbanks-Ochieng, who saw him the same day. The findings were explained to him and his care partner in plain words; he agreed to neuropsychological testing and wants to hear the results with his care partner present. **S**

## Follow-up

Dr. Fairbanks-Ochieng will review the testing with him at the six-week visit and continue his care; the memory clinic will see him again in about a year with repeat testing, or sooner with any of the changes above. **S**

## Guideline basis

- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024), Alzheimer's Association (Alzheimers Dement 2025;21(1):e14337)
- National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021), Neurology 2021;96(18):848-863 (Katz DI et al.)
- VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder (2023), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Depression/Bipolar/Mood Disorders monographs (2026), Aether Forge
- American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023), American Geriatrics Society (Journal of the American Geriatrics Society)
- Guiding an Improved Dementia Experience (GUIDE) Model (2024), Centers for Medicare & Medicaid Services, Innovation Center
